Literature DB >> 1964393

Amphotropic murine leukemia retrovirus is not an acute pathogen for primates.

K Cornetta1, R C Moen, K Culver, R A Morgan, J R McLachlin, S Sturm, J Selegue, W London, R M Blaese, W F Anderson.   

Abstract

The in vivo fate of amphotropic murine leukemia retrovirus was studied in five rhesus monkeys. Retrovirus infused intravenously into 3 normal animals and 1 immunosuppressed animal was cleared rapidly from the circulation and subsequent viremia has not been detected (mean follow-up of 27.4 months). A fifth monkey was immunosuppressed and transplanted with virus-producing autologous fibroblasts in addition to an intraperitoneal injection of virus. This animal was viremic for 2 days and its lymph node cells and peripheral blood mononuclear cells were shown to be producing virus for up to 22 days post-inoculation, but subsequently has been negative after 17.0 months of analysis. In the 5 animals studied (combined mean follow-up of 25.7 months), clinical illness has not been identified at any time. Therefore, murine amphotropic retroviruses do not appear to pose an acute health risk.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1964393     DOI: 10.1089/hum.1990.1.1-15

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  26 in total

Review 1.  Anti-tumor gene therapy.

Authors:  C Cirielli; M C Capogrossi; A Passaniti
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

Review 2.  Retroviral vectors. From laboratory tools to molecular medicine.

Authors:  R G Vile; A Tuszynski; S Castleden
Journal:  Mol Biotechnol       Date:  1996-04       Impact factor: 2.695

Review 3.  Pharmaceutical approach to somatic gene therapy.

Authors:  F D Ledley
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

Review 4.  Retroviral vectors: from cancer viruses to therapeutic tools.

Authors:  A Dusty Miller
Journal:  Hum Gene Ther       Date:  2014-12       Impact factor: 5.695

5.  Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma.

Authors:  Chien-Kuo Tai; Wei Jun Wang; Thomas C Chen; Noriyuki Kasahara
Journal:  Mol Ther       Date:  2005-11       Impact factor: 11.454

6.  Tumor-selective gene expression in a hepatic metastasis model after locoregional delivery of a replication-competent retrovirus vector.

Authors:  Kei Hiraoka; Takahiro Kimura; Christopher R Logg; Noriyuki Kasahara
Journal:  Clin Cancer Res       Date:  2006-12-01       Impact factor: 12.531

7.  Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis.

Authors:  E F Vanin; M Kaloss; C Broscius; A W Nienhuis
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

8.  Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir.

Authors:  L Yang; R Hwang; L Pandit; E M Gordon; W F Anderson; D Parekh
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

9.  Blockade of type I interferon (IFN) production by retroviral replicating vectors and reduced tumor cell responses to IFN likely contribute to tumor selectivity.

Authors:  Amy H Lin; Cindy Burrascano; Par L Pettersson; Carlos E Ibañez; Harry E Gruber; Douglas J Jolly
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

10.  Adaptive evolution of a tagged chimeric gammaretrovirus: identification of novel cis-acting elements that modulate splicing.

Authors:  Christopher R Logg; Brian T Baranick; Nathan A Lemp; Noriyuki Kasahara
Journal:  J Mol Biol       Date:  2007-04-19       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.